The Challenge of Breast Cancer, Especially TNBC

Breast cancer remains the most commonly⁤ diagnosed malignancy among women globally. Within this landscape, ⁢triple-negative breast cancer (TNBC) presents a especially formidable challenge. ⁣Characterized by a lack of common therapeutic targets, TNBC ofen exhibits aggressive⁢ behavior and a high rate of recurrence.A key factor driving this aggressiveness is the “Warburg effect,”‍ where cancer cells prioritize ⁢glucose metabolism into lactate, even in the presence of oxygen. This process creates an acidic environment that promotes metastasis and suppresses the body’s⁤ immune defenses.

Unveiling Lactylation: ‍A⁣ New Layer of Complexity

Recent research,published in Cancer Biology⁢ & Medicine (DOI: 10.20892/j.issn.2095-3941.2025.0173), has identified a novel process called “lactylation” -‍ the modification of proteins and histones by ⁣lactate – as a critical driver of tumor ⁣progression. researchers from Nanjing ⁢Medical University and Zhejiang University systematically reviewed over 120 studies to reveal how this epigenetic modification alters protein function within both cancer cells and the surrounding immune⁣ environment.

How Lactate ‍Fuels Tumor Growth

The accumulation of lactate activates multiple pathways that promote tumor ‍progress.These include:

1. Invasion: Acidification of the tumor microenvironment enhances invasion through the activation of matrix metalloproteinases.
2. Immunosuppression: Lactate induces immunosuppression by upregulating ‍PD-L1 and polarizing macrophages towards an M2 ⁢phenotype.
3. Angiogenesis: Lactate stimulates the formation of new blood vessels (angiogenesis) via VEGF ⁣signaling.

Furthermore,lactylation directly modifies histones (like H3K18la and H4K12la) and crucial tumor suppressor proteins,such as p53,with the AARS1 enzyme playing a central role in this process.

The “Double-Hit” Effect in TNBC

In‍ TNBC, lactylation appears to have a particularly devastating effect,‍ concurrently silencing tumor suppressor ⁤genes and activating oncogenic pathways. This “double-hit”⁤ mechanism explains, in part,‍ the poor prognosis associated with this subtype. Clinical data reveals that patients exhibiting high levels‍ of lactylation markers experience a 3.5-fold increase in mortality rates.

Promising Therapeutic Strategies

Researchers are exploring several avenues for therapeutic intervention. ⁣ In ⁣preclinical studies, a combination therapy utilizing nanoparticle-delivered lactate oxidase (to reduce‍ lactate levels) alongside PD-L1 siRNA (to boost ‍immune response) resulted in a 68% reduction in tumor size in⁣ mouse models. This⁤ suggests a ‍powerful synergistic effect when ⁤addressing both‍ metabolic and immune evasion strategies.

beyond this, pharmaceutical companies are‍ actively investigating small molecules designed to inhibit AARS1-mediated lactylation, offering a potential direct approach to ⁤disrupting this process.

new Diagnostic Horizons

The ⁣research team has developed a 24-gene lactate metabolism signature capable⁢ of⁣ accurately predicting a patient’s⁢ response to treatment. Importantly, they found a strong⁣ correlation ⁣between lactate levels detected through non-invasive ⁢MRI and the aggressiveness of HER2-positive tumors, suggesting that lactate levels could serve as a valuable biomarker for monitoring disease progression.

future Directions & Clinical Opportunities

The findings highlight three immediate clinical opportunities:

• Drug Repurposing: Investigating the use of existing metabolic drugs, such as lactate dehydrogenase (LDH) inhibitors, in combination with ⁣standard therapies.
• Precision Imaging: Developing PET tracers specifically designed to detect lactylation, enabling more precise tumor imaging and monitoring.
• Early Detection: creating⁣ lactylation-based liquid biopsies for the early detection of recurrence.